logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Crenolanib for Advanced or Metastatic Gastrointestinal Stromal Tumours (GISTs) with the D842V Mutation in the PDGFRA Gene

< Back

Crenolanib for Advanced or Metastatic Gastrointestinal Stromal Tumours (GISTs) with the D842V Mutation in the PDGFRA Gene

Drugs

Cancer and Palliative Care

January 2018


GISTs with D842V mutation in PDGFRA are usually resistant to the currently available targeted cancer drugs. Crenolanib is a medicine that specifically blocks the PDGFRA pathway involved in the production of blood vessels that supply the cancer cells, thereby preventing the cancer cells from growing and multiplying. It is being developed for the treatment of advanced or metastatic GISTs with D842V mutation in the PDGFRA gene. This drug is given by mouth. If licensed, crenolanib will offer an additional treatment option for this patient group, particularly those that do not respond to other treatments.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts